To amend sections 1751.92, 3905.24, 3923.87, 3959.01, 3959.111, 3959.12, and 3959.20; to amend, for the purpose of adopting new section numbers as indicated in parentheses, sections 3959.111 (3957.25), 3959.20 (3957.26), and 3959.22 (3957.27); and to enact sections 3957.01, 3957.02, 3957.03, 3957.04, 3957.05, 3957.06, 3957.07, 3957.08, 3957.09, 3957.10, 3957.11, 3957.12, 3957.13, 3957.14, 3957.15, 3957.16, and 3957.99 of the Revised Code to establish a stand-alone licensing process and new contractual requirements for pharmacy benefit managers.
HB229 creates a new, stand-alone regulatory chapter for pharmacy benefit managers (PBMs) in Ohio and shifts PBMs that operate under covered agreements into a separate licensing and oversight framework administered by the Superintendent of Insurance. Beginning January 1, 2027, a person may not solicit or provide PBM services for covered Ohio plans without a PBM license, and applicants must pay filing and renewal fees, receive a certificate of authority, and comply with annual renewal requirements. The bill also defines key terms such as claims processing services, rebates, contracted pharmacies, and pharmacy services administrative organizations, and it excludes certain self-insured plans where federal law preempts state regulation.
The bill imposes detailed contractual and disclosure requirements on PBMs. Covered PBMs must have written agreements with plan sponsors, keep records, disclose compensation and financial arrangements, account for rebates and other benefits, and reveal conflicts of interest and ownership relationships. It also requires insurers to ensure PBMs act as agents owing fiduciary duties in certain arrangements, and it authorizes the superintendent to examine books and records, impose fines, suspend or revoke licenses, and require correction of violations. The bill further prohibits misleading advertising and requires parity in reimbursement between pharmacies and PBM affiliates for the same service.
HB229 would also amend existing Ohio law in section 3959.01 so that, effective January 1, 2027, licensed PBMs are carved out of the general definition of “administrator” for agreements entered into, amended, or renewed on or after that date. That change appears designed to move PBMs from the broader third-party administrator framework into a PBM-specific licensing regime. The bill also makes violations of the new licensing requirement a fourth-degree misdemeanor.
The overall sentiment reflected in the voting history is strongly favorable and bipartisan. The bill advanced unanimously in the House committee and passed both chambers without a recorded dissenting vote, suggesting broad agreement on the need for greater oversight of PBM practices. No committee transcript was provided, so there is no recorded floor or committee debate to indicate opposition in the available materials.
The main points of contention implied by the bill’s structure are the scope of state regulation over PBMs, the extent of required disclosure of rebates and financial arrangements, and the fiduciary-duty requirement in insurer-PBM contracts. The bill also touches on potentially sensitive issues such as affiliate reimbursement parity, proprietary/confidential treatment of data collected by the superintendent, and the interaction between state regulation and federal ERISA preemption for self-insured plans.
HB229 would create a new chapter in the Revised Code governing PBM licensing and conduct, while amending the existing administrator statute to exclude licensed PBMs from the general administrator definition for newer agreements. It would place PBMs under direct oversight of the Department of Insurance, require licensing fees, establish recordkeeping and reporting obligations, authorize examinations and enforcement actions, and impose criminal penalties for unlicensed activity. The bill would also affect insurers, plan sponsors, pharmacies, and PBM affiliates by mandating written contracts, financial disclosures, rebate accounting, and reimbursement rules.
The available voting record shows overwhelming support for the bill, with unanimous committee approval and unanimous passage in both the House and Senate votes listed. That pattern suggests the legislation was viewed favorably across party lines and chambers as a consumer- and transparency-oriented PBM reform measure. Because no committee transcripts were provided, there is no direct evidence of substantive opposition in the record supplied.
The bill’s likely areas of contention are the degree of regulatory burden placed on PBMs, the requirement that PBMs disclose rebates, fees, and related financial arrangements, and the mandate that PBMs act as insurers’ agents with fiduciary duties in covered contracts. Stakeholders such as PBMs, insurers, and pharmacy networks could differ over whether these requirements improve transparency or interfere with contracting and pricing flexibility. Another possible point of dispute is the bill’s treatment of proprietary information as confidential and its interaction with federal preemption for self-insured plans.